Novartis Faces Another Late-Stage Setback as Acquired Drug Fails
Novartis reported a second major clinical trial failure in quick succession, this time involving a drug it obtained through the acquisition of Avidity Biosciences. The late-stage study did not meet its primary endpoint, adding to investor concerns following a recent heart disease setback. The company's stock fell sharply in response to the news.
The pharmaceutical company's newest late-stage trial for an investigational treatment did not reach its main objective. The asset originated from the firm's purchase of Avidity Biosciences.
This outcome marks the second consecutive late-stage disappointment for the company, coming shortly after a separate cardiovascular program failed. The back-to-back misses have amplified investor worries, causing a significant drop in the firm's market value.
Repeated late-stage failures could delay potential new treatment options for patients awaiting novel therapies. Investors may become more cautious about the company's pipeline, potentially affecting funding for future research. Additionally, this trend might influence how the industry evaluates acquisitions, as the risk of integrating unproven assets becomes more apparent. Ultimately, patients and shareholders may feel the consequences of these setbacks.